vimarsana.com
Home
Live Updates
NDA Submitted to FDA for Ivosidenib for Previously Treated I
NDA Submitted to FDA for Ivosidenib for Previously Treated I
NDA Submitted to FDA for Ivosidenib for Previously Treated IDH1-Mutated Cholangiocarcinoma
A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.
Related Keywords
Chris Bowden ,
,
Specialty Pharmacy ,
Oncology ,
Hospital ,
News ,
கிறிஸ் போடன் ,
சிறப்பு மருந்தகம் ,
புற்றுநோயியல் ,
மருத்துவமனை ,
செய்தி ,